Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer

Oncology

Volumn 59, Issue 1, 2000, Pages 14-17

  Kretzschmar, Albrecht ^a   Reichardt, Peter ^a   Thuss Patience, Peter C ^a   Hohenberger, Peter ^b   Benter, Thomas ^a   Dörken, Bernd ^a   Köhne, Claus Henning ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

5 Fluorouracil; Folinic acid; Gastric cancer; Mitomycin C

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0033948591     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012130     Document Type: Article

References (18)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
4. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: A trial of the European organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
5. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
6. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80:269-272.
7. Cervantes A, Aranda E, Sastre J, Abad A, Anton A, Torregrosa F, Carrato A, Navarro M, Llanos M, Garcia-Conde J, Diaz-Rubio E: Weekly high dose continuous infusion 5-fluorouracil in metastatic gastric cancer. A phase II trial of the Spanish group for gastrointestinal tumor therapy. Proc Am Soc Clin Oncol 1997; 16:284a.
8. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 1997;54:275-280.
9. Vanhoefer U, Wilke H, Weh HJ, Clemens M, Harstrick A, Stahl M, Hossfeld DK, Seeber S: Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994;5:850-851.
10. Schnall S, Macdonald JS: Mitomycin therapy in gastric cancer. Oncology 1993;50(suppl I): 70-77.
11. Ross A, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendville J, Watson M, Massey A, Popescu R, Oates J: A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8: 995-1001.
12. Beeker K, Rinas B, Weidmann B, Heider A, Niederle N: High-dose 5-fluorouracil/folinic acid (HD-5-FU/FA) plus mitomycin C (MMC) in patients with refractory colorectal cancer. Proc Am Soc Clin Oncol 1997;16:283a.
13. Wilke H, Korn M, Köhne CH, Fink U, Preusser P, Vanhoefer U, Wiegmann T, Stahl M, Harstrick A, Klaassen U, Schmoll HJ, Seeber S: Phase II results of weekly infusional high dose FU (HD-FU) plus folinic acid (FA) and bi-weekly cisplatin (C) for advanced gastric cancer. Ann Oncol 1996;7:46.
14. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, et al: New developments in the treatment of gastric carconima. Semin Oncol 1990;17:61-70.
15. Wils J: Treatment of gastric cancer. Curr Opin Oncol 1998;10:357-361.
16. Ajani JA: Chemotherapy for gastric carcinoma: New and old options. Oncology (Huntingt) 1998;12:44-47.
17. Poplin EA, LoRusso P, Lokich JJ, Gullo JJ, Leming PD, Schulz JJ, Veach SR, McCulloch W, Baker L, Schein P: Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994;33:415-419.
18. Ross PJ, Cunningham D, Scarffe JH, Nicolson M, Seymour M, Harper P, Price T, Hill A, Anderson H, Iveson T, Hickich T, Lofts F, Norman A: Results of a randomized trial comparing ECF with MCF in advanced oesophagogastric cancer. Proc Am Soc Clin Oncol 1999; 18:272a.